Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target Discover the Best Stocks and Maximize Your Portfolio: ...
Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback